


Patent Claims

1. Quinoline derivatives and quinazoline derivative represented by the following formula (I) and pharmacologically permitted salts thereof



[wherein, R1 and R2 are independently H, 1-5C alkyl or R1 and R2 bond together and form C1-3 alkylene,


and W is CH or N,

wherein,


(I) when W is CH,

(a) X is O or S,

and Q is phenyl group represented by formula (II)




(wherein, m is 1, 2 or 3 and R3 is independently CN, OH, halogen, C1-5 alkyl, C1-4 alkoxy or C2-4 acyl), a group represented by formula (III)



(wherein, m has the same aforesaid meaning, R3' is independently OH, C1-5 alkyl, C1-4 alkoxy, and Y, Z are both or each independently N or CH)

or a group represented by formula (IV)




(wherein, m and R3' have the same aforesaid meanings and R4 is H, C1-5 alkyl or C1-4C acyl),

(b) X is O, S or CH2,

and Q is formula (V)

and

X is O, S or CH₂, and Q is formula (V)



<http://www.risingsun.co.uk>


formula (V).

5. Quinoline derivatives, quinazoline derivatives and pharmacologically permitted salts thereof in accordance with Claim 1, wherein in formula (I), R1 and R2 are independently C1-5 alkyl, and Q is represented by formula (V) [in formula (V), j and k are 0, and B is O, S, NOR6 (wherein, R6 is C1-5 alkyl)].

6. Quinoline derivatives, quinazoline derivatives and pharmacologically permitted salts thereof in accordance with Claim 1, wherein in formula (I), R1 and R2 are independently C1-5 alkyl and Q is represented by formula (V) [in formula (V), j is 0 and k is 1, or j is 1 and k is 0, R5 is hydrogen or methyl, and B is O, S, NH, NCN, NR6 or NOR6 (wherein, R6 is C1-5 alkyl)].

7. Quinoline derivatives, quinazoline derivatives and pharmacologically permitted salts thereof in accordance with Claim 1, wherein in formula (I), R1 and R2 are independently C1-5 alkyl, and Q is represented by formula (V) [in formula (V), j and k are both 1, R5 is independently hydrogen or methyl, and B is O, S, NH, NCN, NR6 or NOR6 (wherein, R6 is C1-5 alkyl)].


8. Quinoline derivatives and quinazoline derivative represented by formula (VI), and pharmacologically permitted salts thereof



(wherein, W is CH or N, R1 and R2 are independently C1-5 alkyl, and A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, isopentyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, naphthyl, furyl, thienyl, pyridyl or pyrimidinyl, wherein these alkyl groups, aryl groups or heteroaryl groups represented by A may have 1-5 substituents selected from the fluoro, chloro, bromo, iodo, cyano, hydroxy, nitro, amino, methylamino, dimethylamino, diethylamino, dipropylamino, dibutyl amino, trifluoromethyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, methoxy, ethoxy, propoxy, isopropoxy, morpholino, pyrrolidino, piperidino or butoxy).


9. Quinoline derivatives and quinazoline derivative represented by formula (VII), and

pharmacologically permitted salts thereof



(wherein, W is CH or N, j is 0 and k is 1, or j is 1 and k is 0, R₁ and R₂ are independently C1-5 alkyl, R₅ is hydrogen or methyl, and A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, isopentyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, naphthyl, furyl, thienyl, pyridyl or pyrimidinyl, and these alkyl groups, aryl groups or heteroaryl groups represented by A may have 1-5 substituents selected from the fluoro, chloro, bromo, iodo, cyano, hydroxy, nitro, amino, methylamino, dimethylamino, diethylamino, dipropylamino, dibutyl amino, trifluoromethyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, methoxy, ethoxy, propoxy, isopropoxy or butoxy).

10. Quinoline derivatives and quinazoline derivative represented by formula (VIII), and pharmacologically permitted salts thereof




(wherein, W is CH or N, R₁ or R₂ is independently C1-5 alkyl, R₅ is independently hydrogen or methyl, A is C1-6 alkyl, C1-4 alkenyl, cyclopentyl, cyclohexyl, cycloheptyl, C1-4 alkoxy carbonyl, phenyl, naphthyl, furyl, thienyl, benzoyl, acetyl, pyridyl, pyrimidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholino, and these alkyl groups, aryl groups or heteroaryl groups represented by A may have 1-5 substituents selected from the halogen, cyano, CO₂H, CONH₂, hydroxy, nitro, amino, C1-4 alkylamino, di-(C1-4 alkyl) amino, C1-5C acyloxy, C1-5 acyl, C1-4 alkylthio, trifluoromethyl, C1-5 alkyl, C1-4 alkoxy, C1-4

©Rising Sun Communications Ltd. <http://www.risingsun.co.uk>

alkoxycarbonyl, N-(C1-4 alkyl) amide, N,N-di-(C1-4 alkyl) amide, C2-4 alkylamide, ethylenedioxy, phenyl, phenoxy, substituted phenyl, benzoyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinolyl or quinazolinyl, and B is O, S, NH, NCN, NR₆ or NOR₆ (wherein, R₆ is methyl)).

11. Quinoline derivatives and quinazoline derivative represented by formula (IX), and pharmacologically permitted salts thereof



(wherein, W is CH or N, R₁ and R₂ are independently C1-5 alkyl, R₅ is independently hydrogen or methyl, A is C1-6 alkyl, C1-4 alkenyl, cyclopentyl, cyclohexyl, cycloheptyl, C1-4 alkoxycarbonyl, phenyl, naphthyl, furyl, thienyl, benzoyl, acetyl, pyridyl, pyrimidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholino, and these alkyl groups, aryl groups or heteroaryl groups represented by A may have 1-5 substituents selected from the halogen, cyano, CO₂H, CONH₂, hydroxy, nitro, amino, C1-4 alkylamino, di-(C1-4 alkyl) amino, C1-5 acyloxy, C1-5 acyl, C1-4 alkylthio, trifluoromethyl, C1-5 alkyl, C1-4 alkoxy, C1-4 alkoxycarbonyl, N-(C1-4 alkyl) amide, N,N-di-(C1-4 alkyl) amide, C2-4 alkylamide, ethylenedioxy, phenyl, phenoxy, substituted phenyl, benzoyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinolyl or quinazolinyl).


12. Quinoline derivatives in accordance with Claim 8 and pharmacologically permitted salts thereof, wherein in formula (VI), W is CH.

13. Quinoline derivatives in accordance with Claim 9 and pharmacologically permitted salts thereof, wherein in formula (VII), W is CH.

14. Quinoline derivatives in accordance with Claim 10 and pharmacologically permitted salts thereof, wherein in formula (VIII), W is CH.


15. Quinoline derivatives in accordance with Claim 11 and pharmacologically permitted salts thereof, wherein in formula (IX), W is CH.

16. Quinoline derivatives and quinazoline derivative represented by formula (X), and pharmacologically permitted salts thereof



(wherein, W is CH or N, R₁ or R₂ are independently C1-5 alkyl, R₅ is independently hydrogen or methyl, and A is C1-5 alkyl, cyclopentyl, cyclohexyl, cycloheptyl, allyl, C1-4 alkoxy carbonyl, phenyl, naphthyl, benzoyl, and these alkyl groups or aryl groups represented by A may have 1-5 substituents selected from the OH, CO₂H, fluoro, chloro, bromo, iodo, nitro, amino, di-(C1-4 alkyl) amino, ethylenedioxy, acetoxy, methylthio, C1-4 alkoxy carbonyl, trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, pyridyl or phenyl).

17. Quinoline derivatives and quinazoline derivative represented by formula (XI), and pharmacologically permitted salts thereof



(wherein, W is CH or N, R₁ or R₂ is independently C1-5 alkyl, R₅ is independently hydrogen or methyl, and A is C1-5 alkyl, cyclopentyl, cyclohexyl, cycloheptyl, allyl, C1-4 alkoxy carbonyl, phenyl, naphthyl, benzoyl, and these alkyl groups or aryl groups represented by A may have 1-5 substituents selected from the OH, CO₂H, fluoro, chloro, bromo, iodo, nitro, amino, di-(C1-4 alkyl) amino, ethylenedioxy, acetoxy, methylthio, C1-4 alkoxy carbonyl, trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, pyridyl or phenyl).

18. Quinoline derivatives in accordance with Claim 1 and pharmacologically permitted salts thereof, wherein in formula (I), W is CH, X is O, R₁ and R₂ are both methyl, and Q is represented by in formula (V) [formula (V), j and k are independently 0 or 1, R₅ is hydrogen, A is C1-5 alkyl, cyclopentyl, cyclohexyl, cycloheptyl, allyl, C1-4 alkoxy carbonyl, phenyl, naphthyl,

benzoyl, and these alkyl groups, aryl groups or heteroaryl groups represented by A may have 1-5 substituents selected from the OH, CO₂H, fluoro, chloro, bromo, iodo, nitro, amino, di-(C1-4 alkyl) amino, ethylenedioxy, acetoxy, methylthio, C1-4 alkoxycarbonyl, trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, pyridyl or phenyl, and B is O, S, NH, NCN, NR₆ or NOR₆ (wherein, R₆ is methyl).

19. A compound in accordance with Claim 16 and pharmacologically permitted salts thereof, wherein in formula (I), W is CH, R₁ and R₂ are both methyl and R₅ are both hydrogen.

20. A compound represented by formula (I) in accordance with Claim 1 and pharmacologically permitted salts thereof, selected from 6,7-dimethoxy-4-(2-methoxyphenoxy) quinoline, 6,7-dimethoxy-4-(3-methoxyphenoxy) quinoline, 6,7-dimethoxy-4-(4-methoxyphenoxy) quinoline, 4-(3-fluoro phenoxy)-6,7-dimethoxy quinoline, 4-(3-hydroxyphenoxy)-6,7-dimethoxy quinoline, 4-(4-bromo phenoxy)-6,7-dimethoxy quinoline, 4-(3,4-dimethoxy phenoxy)-6,7-dimethoxy quinoline, 6,7-dimethoxy-4-(1-naphthyloxy) quinoline, 6,7-dimethoxy-4-(2-naphthyloxy) quinoline, 6,7-dimethoxy-4-(5-methoxy-1-naphthyloxy) quinoline, 6,7-dimethoxy-4-(6-methoxy-2-naphthyloxy) quinoline, 6,7-dimethoxy-4-(7-methoxy-2-naphthyloxy) quinoline, 6,7-dimethoxy-4-(5-quinolyloxy) quinoline, 6,7-dimethoxy-4-(6-quinolyloxy) quinoline, 4-(4-indolyl oxy)-6,7-dimethoxy quinoline, 4-(5-indolyl oxy)-6,7-dimethoxy quinoline, 6,7-dimethoxy-4-(3-methoxyphenyl thio) quinoline and 6,7-dimethoxy-4-(4-methoxyphenyl thio) quinoline.

21. A compound represented by formula (I) in accordance with Claim 1 and pharmacologically permitted salts thereof, selected from the (4-n-butylphenyl) {4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl} methanone, (4-t-butylphenyl) {4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl} methanone, (4-trifluoromethylphenyl) {4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl} methanone, (4-t-butylphenyl) {4-[(6,7-dimethoxy-4-quinazolinyl) oxy] phenyl} methanone, (4-t-butylphenyl) {4-[(6,7-dimethoxy-4-quinolyl) methyl] phenyl} methanone, N-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl}-cyclohexane carboxamide, N-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl}-(4-nitrophenyl) carboxamide, N-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl}-(N,N-dimethylaminophenyl) carboxamide, N-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl}-(4-acetylphenyl) carboxamide, N-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl}-(4-n-butylphenyl) carboxamide, N-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl}-(4-butoxy phenyl) carboxamide, N-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl}-(4-bromo phenyl) carboxamide, N-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl}-cyclopentane carboxamide, N-(4-n-butylphenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl} urea, N-(4-t-butylphenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl} urea, N-(2-trifluoromethylphenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl} urea, N-(3-trifluoromethylphenyl)-N'-{4-[(6,7-dimethoxy-

4-quinolyl) oxy] phenyl) urea, N-(4-trifluoromethylphenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(2-methoxyphenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(3-methoxyphenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(4-methoxyphenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(2-fluorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(3-fluorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(4-fluorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(4-acetylphenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl)-N'-n-propyl urea, N-n-butyl-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(2-fluorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinazolinyl) oxy] phenyl) urea, N-(2-methoxyphenyl)-N'-{4-[(6,7-dimethoxy-4-quinazolinyl) oxy] phenyl) urea, N-(3-methoxyphenyl)-N'-{4-[(6,7-dimethoxy-4-quinazolinyl) oxy] phenyl) urea, N-(4-methoxyphenyl)-N'-{4-[(6,7-dimethoxy-4-quinazolinyl) oxy] phenyl) urea, N-n-butyl-N'-{4-[(6,7-dimethoxy-4-quinazolinyl) oxy] phenyl) urea, {4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) [4-morpholino phenyl] methanone, {4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) [4-pyrrolidino phenyl] methanone, {4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) [4-piperidino phenyl] methanone, N-(2,4-dichlorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(3,4-dichlorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(3,5-dichlorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(4-chloro-2-methylphenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(3-amino-4-chlorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl)-N'-(2-pyridylmethyl) urea, N-(3,4-difluorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(2,4,5-trifluorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea and N-(3-chlorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea, N-(4-hydroxyphenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl) urea.

22. A pharmacological composition containing as effective ingredient at least one member selected from the group comprising compounds in accordance with any one of Claims 1-21 having platelet derived growth factor receptor autophosphorylation inhibitory action and pharmacologically permitted salts thereof.

23. A pharmacological composition which can be used in the therapy of tumor, containing as effective ingredient at least one member selected from the group comprising compounds in accordance with any one of Claims 1-21 and pharmacologically permitted salts thereof.

24. A pharmacological composition which can be used in therapy of psoriasis containing as effective ingredient at least one member selected from the group comprising compounds in accordance with any one of Claims 1-21 and pharmacologically permitted salts thereof.

25. A pharmacological composition which can be used in atherosclerosis therapy containing as effective ingredient at least one member selected from the group comprising compounds in accordance with any one of Claims 1-21 and pharmacologically permitted salts thereof.

26. A pharmacological composition which can be used in therapy of restenosis after percutaneous transluminal coronary angioplasty and by-pass plastic surgery, containing as effective ingredient at least one member selected from the group comprising compounds in accordance with any one of Claims 1-21 and pharmacologically permitted salts thereof.

27. A pharmacological composition which can be used in the therapy of glomerular nephritis containing as effective ingredient at least one member selected from the group comprising compounds in accordance with any of Claims 1-21 and pharmacologically permitted salts thereof.

28. A pharmacological composition which can be used in the therapy of organ fibrosis containing as effective ingredient at least one member selected from the group comprising compounds in accordance with any one of Claims 1-21 and pharmacologically permitted salts thereof.

29. A pharmacological composition which can be used in the therapy of leukaemia containing as effective ingredient at least one member selected from the group comprising compounds in accordance with any one of Claims 1-21 and pharmacologically permitted salts thereof.

30. A pharmacological composition which can be used in therapy of rheumatoid arthritis containing as effective ingredient at least one member selected from the group comprising compounds in accordance with any of Claims 1-21 and pharmacologically permitted salts thereof.

31. A pharmacological composition which can be used in the therapy of glomerular nephritis containing as effective ingredient at least one member selected from the group comprising compounds in accordance with any of Claims 5, 8 or 12 and pharmacologically permitted salts thereof.

32. A pharmacological composition which can be used in the therapy of tumors containing as effective ingredient at least one member selected from the group comprising compounds in accordance with any of Claims 7, 10, 11, 14, 15, 16, 17, 19 and pharmacologically permitted salts thereof.

33. A pharmacological composition which can be used in therapy of leukaemia containing as effective ingredient at least one member selected from the group comprising compounds in accordance with any of Claims 7, 10, 11, 14, 15, 16, 17, 19 and pharmacologically permitted

salts thereof.

34. A pharmacological composition which can be used in the therapy of rheumatoid arthritis containing as effective ingredient at least one member selected from the group comprising compounds in accordance with any of Claims 7, 10, 11, 14, 15, 16, 17, 19 and pharmacologically permitted salts thereof.

35. A process for therapy of abnormal tumor growth comprising the administration of a compound in accordance with any of Claims 1-21 in a therapeutically effective dose to a patient requiring therapy for abnormal tumor growth.

36. A process for therapy of psoriasis comprising the administration of a compound in accordance with any one of Claims 1-21 in a therapeutically effective dose to a patient requiring therapy for psoriasis.

37. A process for therapy of atherosclerosis comprising the administration of a compound in accordance with any one of Claims 1-21 in a therapeutically effective dose to a patient requiring therapy for atherosclerosis.

38. A process for therapy of restenosis after percutaneous transluminal coronary angioplasty and by-pass plastic surgery comprising the administration of a compound in accordance with any one of Claims 1-21 in a therapeutically effective dose to a patient requiring therapy for restenosis after percutaneous transluminal coronary angioplasty and bypass plastic surgery.

39. A process for therapy of glomerular nephritis comprising the administration of a compound in accordance with any one of Claims 1-21 in a therapeutically effective dose to a patient requiring therapy for glomerular nephritis.

40. A process for therapy of organ fibrosis comprising the administration of a compound in accordance with any one of Claims 1-21 in a therapeutically effective dose to a patient requiring therapy for organ fibrosis.

41. A process for therapy of leukaemia comprising the administration of a compound in accordance with any one of Claims 1-21 in a therapeutically effective dose to a patient requiring therapy for leukaemia.

42. A process for therapy of rheumatoid arthritis comprising the administration of a compound in accordance with any one of Claims 1-21 in a therapeutically effective dose to a patient

requiring therapy for rheumatoid arthritis.

43. A process for therapy of glomerular nephritis comprising the administration of a compound in accordance with any one of Claims 5, 8, 12 in a therapeutically effective dose to a patient requiring therapy for glomerular nephritis.

44. A process for therapy of tumor comprising the administration of a compound in accordance with any one of Claims 7, 10, 11, 14, 15, 16, 17, 19 in a therapeutically effective dose to a patient requiring therapy for tumor.

45. A process for therapy of leukaemia comprising the administration of a compound in accordance with any one of Claims 7, 10, 11, 14, 15, 16, 17, 19 in a therapeutically effective dose to a patient requiring therapy for leukaemia.

46. A process for therapy of rheumatoid arthritis comprising the administration of a compound in accordance with any one of Claims 7, 10, 11, 14, 15, 16, 17, 19 in a therapeutically effective dose to a patient requiring therapy for rheumatoid arthritis.

47. Use of the compound in accordance with any one of Claims 1-21 to produce a pharmacological composition.

48. Use of the compound in accordance with any one of Claims 7, 10, 11, 14, 15, 16, 17, 19 to produce an antitumor drug.

49. Use of the compound in accordance with any one of Claims 7, 10, 11, 14, 15, 16, 17, 19 to produce a rheumatoid arthritis therapeutic agent.

Rising Sun Communications Ltd. Terms and Conditions

Rising Sun Communications Ltd. shall not in any circumstances be liable or responsible for the accuracy or completeness of any translation unless such an undertaking has been given and authorised by Rising Sun Communications Ltd. in writing beforehand. More particularly, Rising Sun Communications Ltd. shall not in any circumstances be liable for any direct, indirect, consequential or financial loss or loss of profit resulting directly or indirectly from the use of any translation or consultation services by the customer.

Rising Sun Communications Ltd. retains the copyright to all of its' translation products unless expressly agreed in writing to the contrary. The original buyer is permitted to reproduce copies of a translation for their own corporate use at the site of purchase, however publication in written or electronic format for resale or other dissemination to a wider audience is strictly forbidden unless by prior written agreement.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.